Anatara's Detach reduces piglet mortality in farm trial
18 February, 2015 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) said its Detach product was able to reduce piglet mortality compared with a placebo during an on-site trial at a Victorian farm.
Call for transitional arrangements for R&D Tax incentive cap
17 February, 2015The passage of legislation last week to cap claims on the Research and Development (R&D) Tax Incentive and its retrospective application to 1 July 2014 has prompted calls for the government to provide transitional arrangements for biotech companies abandoned in a difficult position.
Starpharma 1H losses grow on trial spending
17 February, 2015 by Dylan Bushell-EmblingStarpharma (ASX:SPL) reported a wider net loss for the first half of FY15 on increased clinical trial spending, but a capital raising left the company in an improved cash position.
Immuron licenses Travelan in China region
17 February, 2015 by Dylan Bushell-EmblingImmuron (ASX:IM) has licensed its Travelan product - a preventative treatment for travellers diarrhoea - in China and expects the market to eclipse sales of the product in its other regions combined.
PolyNovo names new CEO
16 February, 2015 by Dylan Bushell-EmblingPolyNovo (ASX:PNV) has appointed a new CEO and a regulatory affairs manager as it pursues commercialisation of its products in areas including wound and burns treatment.
CSL boosts half-year profit by 7%
13 February, 2015 by Dylan Bushell-EmblingCSL (ASX:CSL) has reported a net profit for the first half of FY15 of $890.3m, with sales increasing across all its core product segments.
Government joins forces with PUP and Xenophon to stifle biotech innovation
12 February, 2015The government's shock deal with the Palmer United Party and Independent Senator Xenophon to pass legislation in the Senate on Tuesday night to limit the Research and Development (R&D) Tax Incentive deals a further blow to Australia's innovation ecosystem and will impact large and small biotech companies, according to AusBiotech.
Mesoblast well funded despite rising losses
12 February, 2015 by Dylan Bushell-EmblingMesoblast (ASX:MSB) reported a 64% higher net loss for the half-year ending in December, but still ended the period in a strong cash position of $149.2m.
ResMed buys HME software vendor Jaysec
11 February, 2015ResMed (ASX:RMD) has acquired home medical equipment resupply software provider Jaysec and arranged to incorporate Brightree's billing software into its AirView patient management system.
Cochlear posts record revenue for 1H15
10 February, 2015 by Dylan Bushell-EmblingCochlear (ASX:COH) has reported a 240% surge in profit and 18% increase in revenue for the first half of FY15.
AusBiotech submissions say employee share scheme eligibility too tight
10 February, 2015Two AusBiotech submissions have asked the federal government to broaden the eligibility criteria for employee share schemes (ESSs) to allow extra benefits planned for start-up companies to extend to listed companies eligible for the refundable Research and Development (R&D) Tax Incentive.
Orthocell expands into HK with Ortho-ATI
09 February, 2015 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has announced that the first two Hong Kong patients have been treated with its Ortho-ATI tendon repair therapy product.
Nanosonics to build direct sales team in NA
06 February, 2015 by Dylan Bushell-EmblingNanosonics (ASX:NAN) plans to build up a team to conduct direct sales operations in the US and Canada for its ultrasound probe disinfection product trophon EPR.
Delegations set to support global outreach of Australian biotech and medtech
05 February, 2015AusBiotech will be leading missions to the world's largest and most relevant biotech and medtech events over the coming months - in Shanghai, Hong Kong, Korea and USA - to support Australian companies in their outreach and global development.
Invion completes enrolment in INV102 trial
05 February, 2015 by Dylan Bushell-EmblingInvion (ASX:IVX) has completed recruitment in a trial of INV102 in smoking cessation for chronic bronchitis patients, shortly after announcing positive interim results.
